AbbVie (4AB) AI Stock Analysis

Company Guidance

AbbVie raised its full year adjusted earnings per share guidance range by $0.11 at the midpoint to between $13.95 and $13.99 and now expects total net revenues of approximately $67.8 billion, an increase of $200 million, with a roughly 0.5% favorable impact from foreign exchange on full year sales growth; global sales guidance is $34.9 billion for immunology, including Skyrizi revenue of $21.8 billion and Rinvoq revenue of $10.3 billion, $13 billion for neuroscience, including Vraylar sales of $4.2 billion, Botox Therapeutic sales of $4.2 billion and total oral CGRP sales of $3.1 billion, $6.6 billion for oncology, including Venclexta sales of $3.1 billion and Imbruvica sales of $2.1 billion, and $5 billion for aesthetics, including Botox Cosmetic sales of $2.8 billion; AbbVie continues to forecast full year adjusted gross margin above 84% of sales, adjusted R&D expense of approximately $9.8 billion, adjusted SG&A expense of approximately $14.5 billion and adjusted operating margin of approximately 46.7% of sales, including a roughly 1.8% unfavorable impact from acquired IPR&D expense incurred through the third quarter; for the fourth quarter, it anticipates net revenues of approximately $18.4 billion and adjusted earnings per share between $3.83 and $3.87, with both guidance caveats that acquired IPR&D expense may be incurred; the quarterly dividend is increasing 5.2% to $1.82 per share beginning with the dividend payable in February of 2027, and AbbVie remains on track to achieve a net leverage ratio of 2x over the next 2 to 3 years.